The Davos Alzheimer’s Collaborative (DAC) is the first global alliance of governments, nonprofits, academia, and the private sector driving efforts to combat Alzheimer’s disease. DAC aims to invest over $700 million over six years to link, scale, and build on existing efforts across every sector, and foster an innovation ecosystem to coordinate and accelerate the pace of innovation in Alzheimer’s disease research and care and improve brain health globally to achieve equitable and accessible health care.

Why We Must Act Now:

- **The cost and reach of Alzheimer’s disease is staggering despite ongoing efforts to combat the disease:** Alzheimer’s disease impacts more than 55 million families worldwide and the cost to the global economy was $1.3 trillion in 2019 and will only continue to grow in the coming years.¹

- **Lack of diversity has limited our ability to understand the disease and develop precision medicine and new treatments:** To date, nearly all Alzheimer’s research has been conducted on white populations of Western European origin, leaving out 90% of the world, which has limited progress. Yet approximately 70% of Alzheimer’s cases will be in low- and middle-income countries by 2050 due to rapid global life expectancy.¹

- **Healthcare systems are not prepared to meet the challenge:** The number of people living with dementia is projected to triple from over 55 million today to more than 152 million by 2050.² To respond effectively, each nation’s healthcare system must modernize patient care, strengthen primary care, and increase public health efforts to lead to greater detection, diagnosis, and treatment for the millions who need it.

Launched at the World Economic Forum in 2021, The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers, and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.

DAC is Driving Three Key Initiatives:

**GLOBAL COHORTS:** Scientific discovery starts with high-quality data. But 90% of current genetic analysis comes from just 10% of the world’s population. DAC is building global cohorts to advance understanding of Alzheimer’s among diverse populations. This data will provide the foundation for identifying new biomarkers and developing targeted treatments for people worldwide.

**CLINICAL TRIALS:** Progress against Alzheimer’s require faster, less costly clinical trials. DAC is building a global clinical trial network and technology platform that will link clinical trial sites around the world. This will drive innovation by reducing the time and cost of clinical trials, connecting researchers worldwide and accelerating drug development for people in all communities.

**HEALTHCARE SYSTEM PREPAREDNESS:** Catalyzes healthcare system transformation through innovative approaches that measurably increase rates of cognitive screening, early detection, and accurate diagnosis. These initiatives are incorporated into enduring resources and DAC Learning Laboratories, a network of leaders across government, healthcare, and industry, to share best practices that can be scaled globally.

¹World Health Organization Dementia Fact Sheet, March 2023.
THE MISSION

Davos Alzheimer’s Collaborative (DAC) Healthcare System Preparedness (DAC-SP) aims to catalyze global healthcare system transformation that allows those at risk for developing Alzheimer’s and those currently impacted by the disease quicker access to life-changing innovations. To achieve this ambition, DAC-SP brings together leaders from government, healthcare, and industry to drive evidence-based changes to policy and practice. Through implementation science, DAC-SP is evaluating global programs focused on increasing rates of cognitive screening, early detection, and accurate diagnosis of Alzheimer’s disease and related disorders by empowering primary care providers and creating connections to specialized care. Learnings from these programs are synthesized into a practical, digital blueprint, an enduring resource for healthcare systems, to drive adoption of best practices for modernizing Alzheimer’s care and promoting brain health.

THE CHALLENGE

- **Outdated Care Models**: Despite significant progress in Alzheimer’s research and innovation, healthcare systems often use outdated care models. It takes about 17-20 years for new health innovations to become standard practice, and <50% make it into clinical practice.¹
- **Early Detection of Alzheimer’s is Crucial**: Early symptoms of Alzheimer’s disease frequently go undetected or undiagnosed. However, early detection is crucial for improving patients’ lives. Timely and accurate diagnosis ensures that the right patients receive the right treatment at the right time.
- **Healthcare Systems are Unprepared**: With growing prevalence of Alzheimer’s patients, healthcare systems face significant challenges in implementing innovative tools in real-world practice and they lack a clear plan for adopting new care models with quality and efficiency.

WHAT DAC-SP IS DOING

- **Diverse Implementation Programs**: Leading innovative projects focused on seeding healthcare system change with clear actions and goals aimed at sustainable solutions.
- **Global Collaboration**: Bringing together global leaders from government, healthcare, and industry to exchange ideas and collaborate on solutions.
- **Practical Blueprint**: Incorporating insights from the DAC-SP programs into a practical, digital blueprint, an operational roadmap that can be adopted by other healthcare systems to expedite Alzheimer’s care transformation and improve patient outcomes.

PROGRAM ACTIVITIES

- **Early Detection of Cognitive Impairment**: 1st implementation program with two approaches
  - **Flagship Program**
    - 7 healthcare systems across 6 countries: Brazil, Jamaica, Japan, Mexico, Scotland, and US (2 sites)
    - Designed to increase early detection of cognitive impairment in non-specialty settings by implementing a digital cognitive assessment & a blood-based biomarker test.
  - **Grant Program**
    - 12 healthcare systems in 8 countries: Armenia, Brunei, Canada, Cuba, Germany, Japan, Kenya, and US (5 sites)
    - All projects were locally designed and related to the early detection of cognitive impairment symptoms.

- **Accurate Diagnosis Program** is the next project focused on implementation of innovative technology to aid health systems in the timely and accurate diagnosis of Alzheimer’s disease and related disorders, using blood-based biomarkers and confirmatory diagnostic testing.

- DAC-SP hosts bi-annual Learning Laboratory Meetings, organizes Communities of Practice, and partners with major global health forums to bring together leaders across sectors to share learnings and to find solutions that are scalable and sustainable.


https://www.davosalzheimerscollaborative.org/